Protein A affinity chromatography depends on specific binding between the Protein A ligand and the CH2-CH3 junction of the IgG Fc region. Next-generation biologic modalities that lack this region, including naked nanobody therapeutics, Fab fragments, bispecific antibody formats without standard Fc, and antibody-drug conjugates with engineered or silenced Fc, require alternative capture strategies. Nanobody-derived VHH affinity ligands are the technically advanced answer to this platform gap.
Key Takeaways |
|
|
|
|
|
For the broader advanced chromatography context in which VHH affinity capture fits, including the resin families, skid configurations, and scale-up principles that apply to all affinity chromatography, see Advanced Chromatography: Resins, Single-Use Skids, and Scale-Up. For the Protein A purification science that VHH binders extend and complement, see Optimizing Protein A Chromatography for Complex Monoclonal Antibodies.
Protein A Capture and Its Limitations for Next-Generation Formats
The success of Protein A as a platform purification step for monoclonal antibodies reflects an unusual combination of properties: extreme selectivity for IgG-class molecules, high dynamic binding capacity, alkaline-tolerant recombinant variants that withstand repeated CIP cycles, and elution conditions that coincidentally provide a low-pH viral inactivation step in the same unit operation. No other single chromatography step delivers this combination of selectivity, capacity, and orthogonal viral safety in one operation, which is why Protein A has remained the foundation of platform mAb purification for decades despite its high cost.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
The limitation is structural. Protein A binds specifically to the CH2-CH3 junction on the Fc region of IgG molecules. Biologic formats that do not present this structural feature cannot be captured. The affected formats are not marginal applications but represent a substantial and growing fraction of the biologic pipeline:
- Naked VHH nanobody therapeutics: camelid-derived single-domain antibody fragments of twelve to fifteen kilodaltons lacking an Fc region; Protein A binding without Fc is inconsistent and not suitable for production-scale affinity purification
- Fab fragments and F(ab')2 fragments: the antigen-binding portion of IgG after proteolytic cleavage of the Fc; no Fc region present
- Single-chain variable fragments (scFv) and diabodies: engineered antibody fragments comprising only VH and VL domains linked by a peptide
- Bispecific antibodies in Fab x scFv or VHH x IgG formats: one arm lacks an Fc-recognized structural feature, preventing uniform capture across both arms by a single Protein A step
- ADCs with silenced or engineered Fc: where effector function has been ablated or the Fc region structurally modified to prevent Fc receptor binding, the Protein A binding epitope may be partially or fully disrupted
- Non-antibody biologics and biosimilars without Fc: follicle-stimulating hormone, human chorionic gonadotropin, and other glycoprotein biologics with no antibody structural elements
The purification challenge created by these Fc-absent formats is not merely inconvenient. It removes the primary high-selectivity capture step from the purification train, placing the full impurity clearance burden on polishing chromatography steps that were designed to operate on already-partially-purified material. Understanding which VHH-based affinity options are available for each format is the prerequisite for efficient downstream process design. For the polishing approaches applicable after any affinity capture step, see Mixed-Mode Chromatography: Tackling Challenging Impurities.
What Are VHH-Derived Affinity Binders and How Do They Function as Capture Ligands?
VHH domains, also known as single-domain antibody fragments or, in the trademarked nomenclature of Ablynx (now Sanofi), NANOBODIES, are the variable domains of the heavy-chain-only antibodies found naturally in camelid species including llamas, alpacas, and dromedary camels. Unlike conventional antibody variable domains, which associate as VH-VL pairs, VHH domains fold independently into a stable and functional antigen-binding unit of approximately twelve to fifteen kilodaltons with a single elongated CDR3 loop that can access recessed or concave epitopes inaccessible to conventional antibody paratopes.
When used as chromatography ligands, VHH domains are produced recombinantly in Escherichia coli or yeast expression systems, providing a scalable and cost-effective alternative to Protein A production. The VHH is then immobilized on an activated agarose matrix, typically through amine coupling or oriented coupling via an engineered C-terminal tag, creating an affinity resin that captures any molecule presenting the cognate epitope with the selectivity characteristic of an antibody-antigen interaction.
The key engineering advantage of VHH-based ligands is their amenability to directed evolution for improved properties. Alkaline stability, a critical property for CIP compatibility, has been significantly improved in commercially available VHH ligands. A 2025 study published in the journal Viruses screened VHH domains targeting adeno-associated virus capsid proteins and confirmed that selected VHH variants retained full structural integrity and binding activity after exposure to 0.1 M sodium hydroxide, demonstrating the CIP tolerance necessary for production-scale resin reuse. This alkaline stability exceeds that of conventional Protein A in many cases.
The small size of VHH domains relative to Protein A, twelve to fifteen kilodaltons versus forty-two kilodaltons for the full Protein A molecule, allows higher molar ligand density on the resin matrix for a given weight of immobilized protein. Higher ligand density can translate directly into higher dynamic binding capacity, reducing the resin volume required for a given loading mass and potentially improving the economics of the capture step.
Applications by Modality: Matching VHH Binder to Format
The choice of VHH affinity binder for any specific next-generation modality depends on which structural feature of the molecule is both accessible in the loaded format and sufficiently distinct from process-related impurities that selective capture and discriminating elution can be achieved. A 2021 review on downstream purification of bispecific antibodies published in Bioresources and Bioprocessing provides a comprehensive analysis of how sequential VHH capture strategies have been applied to bispecific antibody formats, confirming that matching the capture ligand to the structural features unique to the target molecule, rather than attempting universal Protein A capture, enables significantly higher purity of the desired heterodimeric product.
Modality | Protein A Capture | VHH Binder Option | Rationale and Application |
Naked VHH / nanobody therapeutic | Not reliable; VHH without Fc does not bind Protein A consistently | Anti-VHH affinity resin or IMAC (research only); ion exchange as primary platform alternative for clinical/commercial | No universal VHH capture ligand equivalent to Protein A currently exists; ion exchange chromatography (CEX or AEX) is the practical primary capture approach for clinical manufacturing of VHH therapeutics without Fc fusion |
Fab fragment / F(ab')2 | No; lacks Fc region | CaptureSelect CH1-LX (13 kDa llama VHH targeting CH1 domain); KappaSelect or LambdaFabSelect targeting light chain | CH1-LX captures any Fab-containing format via the CH1 domain; KappaSelect/LambdaFabSelect capture via kappa or lambda light chain. Both enable single-step capture at high selectivity from expression harvest |
Bispecific IgG with kappa and lambda arms | Partial; captures product and homodimer impurities equally via Fc | Sequential: CaptureSelect CH1-LX (captures all) followed by KappaSelect (removes lambda-only homodimers) | Two-resin sequential strategy selectively purifies kappa/lambda heterodimeric bispecific from kappa/kappa and lambda/lambda homodimers; each homodimer binds only one of the two resins |
Bispecific in Fab x scFv format | Only partial; scFv arm does not contribute to Protein A binding | CaptureSelect CH1-LX captures Fab-containing species; KappaSelect removes lambda-only impurities | CH1-LX captures the desired product and impurities containing the Fab arm while allowing scFv monomer to flow through, eliminating it in a single step |
ADC with modified or silenced Fc | Variable; depends on degree of Fc modification. LALA/LALAPG mutations reduce but may not eliminate Protein A binding | CaptureSelect FcXL or alternative Fc-targeted VHH resins; CH1-LX if Fc is modified but CH1 is intact | Selection depends on which Fc modification is present and whether Fc binding is partially retained. Characterize Protein A binding experimentally for each modified Fc variant before selecting VHH alternative |
Adeno-associated virus (AAV) vectors | Not applicable; AAV is a non-antibody biologic with no Fc or antibody structure | VHH affinity resins targeting conserved capsid epitopes; cross-serotype VHH ligands under development for AAV2/8/9 | VHH ligands against conserved capsid regions enable platform capture across multiple AAV serotypes in a single resin format, potentially replacing serotype-specific capture approaches with one validated purification step |
Non-antibody glycoprotein biosimilars (FSH, hCG) | Not applicable; no antibody structural features | Product-specific VHH affinity resins engineered for the specific glycoprotein structure | VHH ligands have been developed and used in commercial manufacturing of gonadotropin biosimilars, providing a single-step selective capture equivalent to the role Protein A plays for mAbs |
How Do VHH Capture Ligand Properties Compare to Protein A?
VHH-based affinity resins share the fundamental operating principle of Protein A: an immobilized binder providing highly selective capture through a specific molecular interaction, but differing in engineering properties that affect resin lifetime, operating conditions, scalability, and the economics of the capture step.
Property | Protein A resin | VHH-derived affinity resin |
Ligand molecular weight | Approximately forty-two kilodaltons for full Protein A (five IgG-binding domains); recombinant variants such as Protein Z are smaller at approximately fourteen kilodaltons | Approximately twelve to fifteen kilodaltons per VHH domain; small size enables high molar ligand density on the resin matrix |
Target structural feature | CH2-CH3 junction of IgG Fc region; specific for IgG-class molecules with intact Fc | Engineerable to any accessible structural feature; CH1 domain, kappa light chain, lambda light chain, VHH domain, capsid protein, glycoprotein epitope |
Alkaline CIP stability | Limited for native Protein A; recombinant alkali-tolerant variants (e.g., MabSelect SuRe) provide substantially improved stability at 0.1 to 0.5 M NaOH for hundreds of cycles | Engineerable; wild-type VHH may have variable alkaline stability; selected or engineered alkali-stable variants have been demonstrated at 0.1 M NaOH; generally comparable to or better than Protein A with optimized engineering |
Elution pH | Typically pH 2.5 to 3.5; enables simultaneous low-pH viral inactivation in the eluate pool | Product-specific; often higher pH than Protein A (pH 3.5 to 5.0 for some VHH ligands), reducing exposure to acidic conditions that may be poorly tolerated by some next-gen modalities |
Ligand leachables profile | Well-characterized; Protein A leachables are monitored in commercial mAb drug substance; regulatory precedent established | Requires individual characterization for each novel VHH ligand; no prior regulatory precedent for new structures; additional analytical method development required |
Manufacturing cost | High; Protein A produced by recombinant fermentation with complex purification | Potentially lower; VHH produced in E. coli or yeast with simpler purification; benefit depends on scale and commercial availability |
Polishing and Orthogonal Steps After VHH Capture
VHH affinity capture, like Protein A for mAbs, is a high-selectivity step that delivers a partially purified intermediate rather than drug-substance-grade purity. The polishing train following VHH capture must address host cell proteins, DNA, aggregates, and in the case of bispecific antibodies, residual product-related impurities such as homodimers or misassembled species that co-purified with the target.
The design of the polishing sequence after VHH capture depends heavily on the specific modality and its impurity profile. For Fab fragments, which are small and highly charged relative to IgG, ion exchange chromatography selectivity under pH and conductivity conditions that work for full-length antibodies may need significant re-optimization. The smaller size of Fab fragments also creates challenges for ultrafiltration membrane molecular weight cutoff selection, requiring tighter membranes (typically three to five kilodaltons rather than thirty kilodaltons) to achieve adequate product retention during concentration and diafiltration.
Mixed-mode chromatography is particularly well-suited to polishing applications following VHH affinity capture because its combined electrostatic and hydrophobic interaction mechanism provides selectivity orthogonal to the charge-based separation of standard ion exchange. For next-generation modalities with unusual charge or hydrophobicity profiles relative to IgG, mixed-mode resins often provide clearance of co-purifying impurities that bind similarly to the target on single-mode resins. The technical basis for this orthogonal selectivity is covered in depth in Mixed-Mode Chromatography: Tackling Challenging Impurities.
VHH-captured intermediates that will proceed through single-use polishing skids benefit from understanding the flow rate and residence time requirements specific to the smaller VHH-captured molecule formats. The operating parameters for single-use skids optimized for mAb purification may require adjustment for smaller fragment formats where dispersion and residence time distribution are more sensitive to column geometry. The related coverage of The Rise of Single-Use Chromatography Skids in GMP Manufacturing provides the single-use skid context relevant to implementing VHH capture steps in a GMP facility.
What Are the Regulatory Expectations for Novel Affinity Ligand Systems?
Novel VHH affinity ligands, unlike Protein A with its decades of regulatory precedent, require individual characterization of their safety profile when used in drug substance manufacturing. The primary regulatory concern is ligand leachables: VHH protein fragments that may be released from the resin matrix and co-purify with the drug substance in amounts that could pose patient safety or immunogenicity risks if not controlled.
Regulatory expectations for novel affinity ligands are addressed in ICH guideline Q6B, which covers specifications for biotechnological and biological products, and in the FDA and EMA guidances on manufacturing process characterization and validation for biologics. Key requirements include: analytical method development and validation for detection of ligand-derived species in the drug substance; demonstration that ligand leachables are controlled to defined acceptance limits that have been assessed for safety; and characterization of ligand stability and performance across the intended operating lifetime of the resin. For the broader specifications framework applicable to all downstream chromatography steps, see the purification applications and specifications context in the Separation Science biomolecule purification resource.
The immunogenicity risk of VHH-derived ligand leachables is a specific consideration for novel camelid-derived sequences, where the non-human framework regions of the VHH domain may present immunogenic epitopes if present in the drug substance above safe limits. A 2025 publication on the development of drug-like humanized VHH antibody libraries confirmed that humanization of camelid VHH sequences, replacing camelid framework residues with human equivalents while preserving the CDR3 loop that defines binding specificity, is now a standard approach in both VHH therapeutic development and, increasingly, VHH ligand engineering to reduce immunogenicity risk of ligand-derived leachables.
The practical regulatory pathway for a novel VHH affinity resin in GMP manufacturing mirrors the general pathway for any novel process material: generate extractables data under exaggerated extraction conditions to identify all releasable species; characterize the chemistry and toxicology of each identified compound; establish process-specific leachables data in representative process conditions to demonstrate that operational levels are below the safety-qualified thresholds; and document the stability of the ligand-resin system across the validated operating lifetime.
This article was produced under Separation Science's AI Editorial Guidelines.
